0001209191-23-042551.txt : 20230718
0001209191-23-042551.hdr.sgml : 20230718
20230718160013
ACCESSION NUMBER: 0001209191-23-042551
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230714
FILED AS OF DATE: 20230718
DATE AS OF CHANGE: 20230718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CAGNONI PABLO J
CENTRAL INDEX KEY: 0001205703
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 231094235
MAIL ADDRESS:
STREET 1: ONYX PHARMACEUTICALS, INC.
STREET 2: 249 E. GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-14
0
0000879169
INCYTE CORP
INCY
0001205703
CAGNONI PABLO J
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19083
0
1
0
0
President, R&D
0
Common Stock
2023-07-14
4
A
0
9668
0.00
A
202068
D
Employee Stock Option (right to buy)
61.76
2023-07-14
4
A
0
20275
0.00
A
2033-07-13
Common Stock
20275
20275
D
Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Pablo Cagnoni's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
Including the July 14, 2023 RSU Grant, this includes an aggregate of 202,068 shares of common stock issuable pursuant to previously reported RSUs that have not vested.
The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
/s/ Elizabeth Feeney, Attorney-In-Fact
2023-07-18